Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O’Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. O’Day is currently the CEO of Roche Pharmaceuticals. He has held the position since 2012, and prior to that led Roche Diagnostics.
Are novel antibiotics worth investing in?
BackgroundIn autumn, stakeholders across the globe pledged to take more action in the fight against antimicrobial resistance (AMR). Whereas from the push side new public and private initiatives appeared on the screen, discussion about which pull mechanism should be started first is in full swing. Meanwhile, small and medium-sized companies combine forces aiming to propel preclinical and early clinical R&D.
Oxford BioTherapeutics in $450 deal with Wuxi Biologics
Latest NewsImmuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies for combination therapies using Wuxi Biologics’ WuXiBody platform.
Gilead names Daniel O’Day CEO
AppointmentsGilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O’Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. O’Day is currently the CEO of Roche Pharmaceuticals. He has held the position since 2012, and prior to that led Roche Diagnostics.
Smart sealer
ProductsLiquid Plate Sealer® is a coating stabilizer for antibodies and antigens coated on polystyrene- or glass-surfaces.
Diabetes doubles risk for heart failure
Latest NewsAn analysis of health records of the whole Scottish population aged ?30 years revealed that people with diabetes have an increased risk for heart failure.
Genentech CEO to switch to Roche Pharma
AppointmentsWilliam Anderson, currently CEO of Genentech, will be appointed CEO Roche Pharmaceuticals effective 1 January 2019. He will be based in Basel, report to Severin Schwan, Roche Group CEO and become a member of the Corporate Executive Committee.
DIA Europe 2019: Why attend?
Sponsored PublicationsDIA Europe is more than a traditional meeting. It’s a chance to learn, engage, and grow as a healthcare professional alongside thousands of cross-functional collaborative leaders.
AZ checkpoint blocker combo fails in head and neck cancer
Latest NewsBritish drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.
Phenol, guanidinium and ethanol affect PCR or NGS analysis
Sponsored PublicationsBioEcho Life Sciences develops novel kits for the isolation and processing of DNA and RNA. The new EchoCLEAN CleanUp kits for rapid single-step purification of RNA or DNA samples with removal of any residual denaturating salts or organic solvents increase the reliability in PCR and NGS analysis.
XyloCor Therapeutics bags US$17m in Series A financing
Latest NewsLSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist XyloCor Therapeutics.